Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PfEMP1 is a highly variable surface antigen expressed on infected erythrocytes. It mediates cytoadherence to endothelial cells, leading to sequestration of infected cells in various organs. This process contributes to severe malaria pathologies. PfEMP1 is a major target of acquired immunity and a key virulence factor. Its sequence diversity allows for antigenic variation and immune evasion. Targeting PfEMP1 is a promising strategy for preventing severe malaria.
Inhibition of PfEMP1 binding to endothelial receptors (e.g., ICAM-1, EPCR) to prevent cytoadherence and sequestration of infected erythrocytes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum Erythrocyte Membrane Protein 1 (PfEMP1).